These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21982718)

  • 21. Advances in automated docking applied to human immunodeficiency virus type 1 protease.
    Miller MD; Sheridan RP; Kearsley SK; Underwood DJ
    Methods Enzymol; 1994; 241():354-70. PubMed ID: 7854188
    [No Abstract]   [Full Text] [Related]  

  • 22. Enamino-oxindole HIV protease inhibitors.
    Eissenstat M; Guerassina T; Gulnik S; Afonina E; Silva AM; Ludtke D; Yokoe H; Yu B; Erickson J
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5078-83. PubMed ID: 22749283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Revealing interaction mode between HIV-1 protease and mannitol analog inhibitor.
    Yan GW; Chen Y; Li Y; Chen HF
    Chem Biol Drug Des; 2012 Jun; 79(6):916-25. PubMed ID: 22296911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
    Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
    BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
    Qiu X; Zhao GD; Tang LQ; Liu ZP
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural analysis of lead fullerene-based inhibitor bound to human immunodeficiency virus type 1 protease in solution from molecular dynamics simulations.
    Lee VS; Nimmanpipug P; Aruksakunwong O; Promsri S; Sompornpisut P; Hannongbua S
    J Mol Graph Model; 2007 Sep; 26(2):558-70. PubMed ID: 17468026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, biologic evaluation, and SAR of novel pseudo-peptide incorporating benzheterocycles as HIV-1 protease inhibitors.
    He M; Zhang H; Yao X; Eckart M; Zuo E; Yang M
    Chem Biol Drug Des; 2010 Aug; 76(2):174-80. PubMed ID: 20572811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. I36T↑T mutation in South African subtype C (C-SA) HIV-1 protease significantly alters protease-drug interactions.
    Maseko SB; Padayachee E; Govender T; Sayed Y; Kruger G; Maguire GEM; Lin J
    Biol Chem; 2017 Sep; 398(10):1109-1117. PubMed ID: 28525359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unraveling HIV protease flaps dynamics by Constant pH Molecular Dynamics simulations.
    Soares RO; Torres PHM; da Silva ML; Pascutti PG
    J Struct Biol; 2016 Aug; 195(2):216-226. PubMed ID: 27291071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural and dynamical properties of different protonated states of mutant HIV-1 protease complexed with the saquinavir inhibitor studied by molecular dynamics simulations.
    Aruksakunwong O; Wittayanarakul K; Sompornpisut P; Sanghiran V; Parasuk V; Hannongbua S
    J Mol Graph Model; 2006 Nov; 25(3):324-32. PubMed ID: 16504560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure, dynamics and solvation of HIV-1 protease/saquinavir complex in aqueous solution and their contributions to drug resistance: molecular dynamic simulations.
    Wittayanarakul K; Aruksakunwong O; Sompornpisut P; Sanghiran-Lee V; Parasuk V; Pinitglang S; Hannongbua S
    J Chem Inf Model; 2005; 45(2):300-8. PubMed ID: 15807491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and molecular modelling studies of novel carbapeptide analogs for inhibition of HIV-1 protease.
    Pawar SA; Jabgunde AM; Govender P; Maguire GE; Kruger HG; Parboosing R; Soliman ME; Sayed Y; Dhavale DD; Govender T
    Eur J Med Chem; 2012 Jul; 53():13-21. PubMed ID: 22542107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interdependence of Inhibitor Recognition in HIV-1 Protease.
    Paulsen JL; Leidner F; Ragland DA; Kurt Yilmaz N; Schiffer CA
    J Chem Theory Comput; 2017 May; 13(5):2300-2309. PubMed ID: 28358514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of HIV-1 protease by a boron-modified polypeptide.
    Pivazyan AD; Matteson DS; Fabry-Asztalos L; Singh RP; Lin PF; Blair W; Guo K; Robinson B; Prusoff WH
    Biochem Pharmacol; 2000 Oct; 60(7):927-36. PubMed ID: 10974201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi-drug resistance profile of PR20 HIV-1 protease is attributed to distorted conformational and drug binding landscape: molecular dynamics insights.
    Chetty S; Bhakat S; Martin AJ; Soliman ME
    J Biomol Struct Dyn; 2016; 34(1):135-51. PubMed ID: 25671669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.
    Ghosh AK; Gemma S; Takayama J; Baldridge A; Leshchenko-Yashchuk S; Miller HB; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
    Org Biomol Chem; 2008 Oct; 6(20):3703-13. PubMed ID: 18843400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.
    Prasad JV; Para KS; Tummino PJ; Ferguson D; McQuade TJ; Lunney EA; Rapundalo ST; Batley BL; Hingorani G; Domagala JM
    J Med Chem; 1995 Mar; 38(6):898-905. PubMed ID: 7699705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions.
    Seibold SA; Cukier RI
    Proteins; 2007 Nov; 69(3):551-65. PubMed ID: 17623840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors.
    Andersson HO; Fridborg K; Löwgren S; Alterman M; Mühlman A; Björsne M; Garg N; Kvarnström I; Schaal W; Classon B; Karlén A; Danielsson UH; Ahlsén G; Nillroth U; Vrang L; Oberg B; Samuelsson B; Hallberg A; Unge T
    Eur J Biochem; 2003 Apr; 270(8):1746-58. PubMed ID: 12694187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem.
    Dunn BM; Pennington MW; Frase DC; Nash K
    Biopolymers; 1999; 51(1):69-77. PubMed ID: 10380354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.